Explore /
Poster
/ Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Final efficacy and safety results.

Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Final efficacy and safety results.

Authors

Adam Kessel

Huntsman Cancer Institute-University of Utah Health Care, Salt Lake City, UT

Adam Kessel , Taylor Ryan McFarland , Nicolas Sayegh , Kathryn Morton , Deepika Sirohi , Manish Kohli , Umang Swami , Roberto Nussenzveig , Neeraj Agarwal , Benjamin Louis Maughan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Prostate Cancer - Advanced Disease

Track

Prostate Cancer - Advanced

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02199197

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr 135)

DOI

10.1200/JCO.2021.39.6_suppl.135

Abstract #

135

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

Poster

2020 Genitourinary Cancers Symposium

$Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Long-term follow up of secondary endpoints.$